Now Approved: U.S. FDA approves product to reduce the incidence of catheter-related bloodstream infections (CRBSIs) under special pathway for patients receiving hemodialysis.

Matt David, M.D.

September 1, 2022

Matt David was appointed Executive Vice President and Chief Financial Officer in May 2020 and also served as CorMedix’s interim CEO from October 2021 to May 2022. He leads the company’s finance and investor relations activities. Prior to joining CorMedix, Dr. David was Head of Strategy at Ovid Therapeutics and spent the majority of his career in healthcare investment banking roles where he advised life sciences companies on a broad range of financing and strategic transactions. Earlier in his career, Dr. David spent time as a research analyst covering the pharma sector. Dr. David received his M.D. from NYU School of Medicine and his undergraduate degree from Dartmouth College.